| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7K | -91.8% | — |
| R&D Expense | $180K | -38.7% | +2165.2% |
| SG&A Expense | $1.4M | -68.0% | +73.1% |
| Pre-tax Income | -$4.4M | +5.6% | -437.4% |
| Net Income | -$4.4M | +5.6% | -437.4% |
| EPS (Basic) | -$0.13 | +13.3% | -333.3% |
| EPS (Diluted) | -$0.13 | +13.3% | -333.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Short-term Investments | $1.9M | — | — |
| Accounts Receivable | $5K | -94.5% | — |
| Current Assets | $2.9M | -64.0% | — |
| Total Assets | $9.7M | +14.5% | — |
| Current Liabilities | $4.0M | -20.2% | — |
| Total Liabilities | $4.0M | -19.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.0M | — | — |
| Investing Cash Flow | -$2.0M | — | — |
| Financing Cash Flow | $7.8M | — | — |
| Stockholders' Equity | $5.7M | +63.5% | +841.7% |